Analyst Reco. AlloVir, Inc.

Equities

ALVR

US0198181036

Delayed Nasdaq Other stock markets 11:46:17 2024-04-25 am EDT			5-day change	1st Jan Change
0.7899 ^USD	+1.27%		+5.78%	+15.48%

Mar. 20	North American Morning Briefing : Markets on Hold -2-	DJ
Mar. 15	AlloVir, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : S&P 500 Hovers Near Record as Interest Rate Optimism Holds Sway	Dec. 27	DJ
Morgan Stanley Downgrades AlloVir to Equalweight From Overweight, Cuts Price Target to $1 From $20	Dec. 22	MT
Leerink Partners Downgrades AlloVir to Market Perform From Outperform, Cuts Price Target to $1 From $14	Dec. 22	MT
Piper Sandler Downgrades AlloVir to Neutral From Overweight, Cuts Price Target to $1.50 From $27	Dec. 22	MT
JPMorgan Downgrades AlloVir to Underweight From Overweight	Dec. 22	MT
AlloVir Shares Rise After BofA Securities Cites 'Compelling Story,' Initiates Coverage With a Buy	23-08-18	MT
BofA Securities Starts AlloVir at Buy	23-08-18	MT
SVB Securities Adjusts Price Target on AlloVir to $19 From $16, Maintains Outperform Rating	23-04-26	MT
SVB Securities Adjusts Price Target on AlloVir to $19 From $25, Maintains Outperform Rating	23-01-23	MT
SVB Securities Adjusts Price Target on AlloVir to $25 From $24, Maintains Outperform Rating	22-11-07	MT
Morgan Stanley Cuts Price Target on AlloVir to $27 From $32, Maintains Overweight Rating	22-09-09	MT
Piper Sandler Adjusts AlloVir's Price Target to $30 From $34, Reiterates Overweight Rating	22-08-05	MT
SVB Securities Adjusts AlloVir's Price Target to $23 from $30, Keeps Outperform Rating	22-07-28	MT
Piper Sandler Adjusts AlloVir's Price Target to $34 From $55, Reiterates Overweight Rating	22-05-19	MT
SVB Leerink Adjusts AlloVir Price Target to $30 From $32, Maintains Outperform Rating	22-02-10	MT
BMO Capital Starts AlloVir at Outperform with $130 Price Target	22-02-01	MT
Morgan Stanley Adjusts AlloVir Price Target to $32 From $45, Maintains Overweight Rating	22-02-01	MT
Morgan Stanley Adjusts AlloVir's Price Target to $45 from $48, Keeps Overweight Rating	22-01-18	MT
SVB Leerink Adjusts AlloVir's Price Target to $32 from $37, Keeps Outperform Rating	21-12-17	MT
SVB Leerink Adjusts Price Target on AlloVir to $37 from $41, Keeps Outperform Rating	21-11-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. AlloVir, Inc.

Equities

ALVR

US0198181036

Analyst Reco.

Filters